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Abstract 17 
Metabolite annotation and identification are primary challenges in untargeted metabolomics 18 
experiments. Rigorous workflows for reliable annotation of mass features with chemical structures or 19 
compound classes are needed to enhance the power of untargeted mass spectrometry. High-resolution 20 
mass spectrometry considerably improves the confidence in assigning elemental formulas to mass 21 
features in comparison to nominal mass spectrometry, and embedding of fragmentation methods 22 
enables more reliable metabolite annotations and facilitates metabolite classification. However, the 23 
analysis of mass fragmentation spectra can be a time-consuming step and requires expert knowledge. 24 
This study demonstrates how characteristic fragmentations, specific to classes of compounds, can be 25 
used to systematically analyze their presence in complex biological extracts like urine that underwent 26 
untargeted mass spectrometry combined with data dependent or targeted fragmentation. Human urine 27 
extracts were analyzed using normal phase liquid chromatography (HILIC) coupled to an Ion Trap-28 
Orbitrap hybrid instrument. Subsequently, mass chromatograms and CID and HCD fragments were 29 
annotated using the freely available MAGMa software (www.emetabolomics.org).  30 
Acylcarnitines play a central role in energy metabolism by transporting fatty acids into the 31 
mitochondrial matrix. By filtering on a combination of a mass fragment and neutral loss designed 32 
based on the MAGMa fragment annotations, we were able to classify and annotate 50 acylcarnitines 33 
in human urine extracts, based on high-resolution mass spectrometry HCD fragmentation spectra at 34 
different energies for all of them. Of these annotated acylcarnitines, 31 are not described in HMDB 35 
yet and for only 4 annotated acylcarnitines the fragmentation spectra could be matched to reference 36 
spectra. Therefore, we conclude that the use of mass fragmentation filters within the context of 37 
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untargeted metabolomics experiments is a valuable tool to enhance the annotation of small 38 
metabolites. 39 
 40 
1. Introduction 41 
Mass spectrometry in conjunction with liquid chromatography has been successfully used for two 42 
decades to profile extracts of complex biological samples. In recent years, the ability to identify and 43 
annotate hundreds of compounds simultaneously in a single sample has been a major driving force 44 
behind the expansion of the technology known as metabolomics. (Dunn et al., 2013). However, 45 
assigning molecular structures to detected mass signals has proven to be a primary challenge in 46 
metabolomics studies (van der Hooft et al., 2013). Modern mass spectrometers are capable of 47 
capturing the molecular masses of ionized metabolites at high-resolution, potentially providing 48 
scientists with an unprecedented insight in complex biological mixtures such as cell extracts, plasma 49 
or urine. High-resolution mass spectrometers such as the orbitrap provide accurate mass 50 
measurements and are thus able to reliably distinguish co-eluting isobaric species of marginally 51 
different mass (Watson and Sparkman, 2007;Makarov and Scigelova, 2010), in contrast to mass 52 
spectrometers with nominal mass detection. Furthermore, many modern mass spectrometers can trap 53 
ionized metabolites in collision cells and generate fragments that can be analyzed at high-resolution 54 
too (Schuhmann et al., 2011;Van der Hooft et al., 2011;Van der Hooft et al., 2012b). Analysis of the 55 
resulting fragments and neutral losses usually provides additional structural information about the 56 
fragmented mass as well as more constraints for its elemental formula. 57 
Recent studies have demonstrated the use of an ion trap - orbitrap hybrid mass spectrometer to 58 
fragment reference compounds or metabolites present in biological extracts (Kasper et al., 59 
2012;Rojas-Cherto et al., 2012;van der Hooft et al., 2012a). Two types of fragmentation are 60 
commonly employed in metabolomics studies: collision induced dissociation (CID) or higher-energy 61 
collisional dissociation (HCD), each of them usually providing slightly different fragmentation 62 
spectra for the same fragmented metabolite. High-resolution mass spectrometry combined with 63 
fragmentation greatly enhances our ability to structurally elucidate compounds, but assigning a 64 
chemical annotation to observed mass features remains a major bottleneck when using untargeted 65 
metabolomics approaches (Kind and Fiehn, 2010;Wishart, 2011;Dunn et al., 2013;van der Hooft et 66 
al., 2013). 67 
Although untargeted metabolomics studies aspire to capture and characterize the entire metabolome 68 
of a biological sample, in practice trade-offs are made during sample preparation and mass detection 69 
as to which metabolites are actually measured. Complex urine extracts prepared for ‘normal phase’ 70 
chromatography (i.e., hydrophilic interaction chromatography, HILIC) typically contain several 71 
thousands of small polar metabolites covering multiple chemical classes that can be separated and 72 
detected in a mass chromatogram (Creek et al., 2011;Zhang et al., 2012). Here, we describe the 73 
annotation of multiple detected acylcarnitines using global HILIC - high-resolution tandem mass 74 
spectrometry approaches. Acylcarnitines are all derivatives of carnitine, carrying different fatty acids 75 
(Thompson et al., 2012). These metabolites play an important role in energy metabolism, for example 76 
by transporting acyl moieties into the mitochondria where they undergo beta oxidation, and specific 77 
enzymes and transporter proteins exist that translocate acylcarnitines in and out of the cells and blood 78 
stream and excessive acylcarnitines are excreted in the urine (Frayn, 2010). Acylcarnitine 79 
concentrations vary depending on the energy status of the human body (Thompson et al., 2012). 80 
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Irregular urinary and serum acylcarnitine patterns have been identified as biomarkers for several 81 
energy related diseases including diabetes mellitus (Dudzik et al., 2014) and metabolic syndrome 82 
(Patterson et al., 2009;Peng et al., 2013a).  Moreover, acylcarnitine patterns were found to be markers 83 
for inborn metabolic distortions caused by malfunctioning of enzymes involved in fatty acid 84 
metabolism (Ellis et al., 2007;Gucciardi et al., 2012).  85 
Both reversed phase (C18 based) and HILIC chromatography, often combined with dedicated sample 86 
preparation, have been used to separate acylcarnitines from other urinary metabolites and from each 87 
other (Yang et al., 2007;Gucciardi et al., 2012;Peng et al., 2013b). Gas chromatography coupled to 88 
mass spectrometry has also been used successfully to detect and characterize acylcarnitine species 89 
(Libert et al., 2000). The most comprehensive study on acylcarnitine species in urine up to date 90 
reported over 350 species using a 2 hours UPLC run following  sample preparation focused 91 
specifically on this class of compound, and a targeted nominal mass fragmentation approach (Zuniga 92 
and Li, 2011). In contrast, untargeted mass spectrometry experiments aim to identify a diverse 93 
spectrum of compounds without being optimized for particular chemical classes. Within this context, 94 
the use of collision induced fragmentation of metabolites to assess their structure can serve as a 95 
means of annotating substructures or structures to metabolites in complex mixtures. The aim of this 96 
study was to explore the use of data dependent and targeted CID and HCD fragmentation in 97 
combination with a generic pHILIC or HILIC gradient coupled to untargeted high-resolution mass 98 
spectrometry to classify and annotate acylcarnitines present among the broad spectrum of polar 99 
metabolites that can be detected in human urine extracts. Furthermore, the generated high-resolution 100 
fragmentation spectra were used to obtain structural information on the fatty acyl moiety linked to the 101 
carnitine molecule.  102 
Fragmentation spectra obtained from urine extracts were first annotated using the MAGMa software 103 
developed by Ridder et al. (www.emetablomics.org, (Ridder et al., 2014a)) with potential candidates 104 
from a compound database containing known and predicted human metabolites (HMDB 105 
[www.hmdb.ca]). Then, based on fragment annotation as proposed by the MAGMa software and as 106 
proposed in literature, key fragments or losses were determined in order to create a mass 107 
fragmentation filter that uniquely screens for the acylcarnitine structures. Subsequently, CID-MS
n
 108 
and HCD type fragmentation files were manually studied to assess the designed filter for 109 
acylcarnitine classification. Next, the mass fragmentation filter was used to annotate acylcarnitines 110 
fragmented by data dependent and independent fragmentation. A graphical outline of the approach is 111 
presented in Figure 1. All acylcarnitine species that could be annotated in the pHILIC and HILIC 112 
gradients are listed in the Supplementary Table. 113 
 114 
  115 
Last Name author1 et al.  Running Title 
 4 This is a provisional file, not the final typeset article 
2. Materials and methods 116 
 117 
2.1 Materials 118 
HPLC-grade methanol, acetonitrile, isopropanol, and analytical reagent grade chloroform were 119 
acquired from Fisher Scientific, Loughborough, UK. HPLC grade H2O was purchased from VWR 120 
Chemicals, Fountenay-sous-Bois, France. Formic acid (for mass spectrometry) and ammonium 121 
carbonate were acquired from Fluka Analytical (Sigma Aldrich), Steinheim, Germany. L-carnitine 122 
(≥98%) was obtained from Sigma-Aldrich, St. Louis, USA. 123 
Urine samples from anonymized healthy human volunteers were used from a clinical data set in the 124 
Glasgow Polyomics archive. The seven urine samples used in this study were numbered 1 to 7, urines 125 
1 – 4 were used for data dependent fragmentation approaches, where urines 5 – 7 were used for 126 
targeted fragmentation of suspected low abundant acylcarnitines, as summarized in Table 1. 127 
 128 
Table 1: Schematic experimental design of human urines used in this study. 129 
 130 
Urine # Chromatography Mass Spectrometry Usage 
1 pHILIC Untargeted Filter generation & application 
2 pHILIC Untargeted Filter generation & application 
3 HILIC Untargeted Filter application 
4 HILIC Untargeted Filter application 
5 HILIC Targeted Filter application 
6 HILIC Targeted Filter application 
7 HILIC Targeted Filter application 
These samples were obtained as part of an ethical approved project, granted by the MVLS College 131 
Ethics Committee of the University of Glasgow, Glasgow, UK (Project No: 2012061). The 132 
volunteers gave their consent for conducting metabolomics studies with their urine samples. 133 
 134 
2.2 Methods 135 
2.2.1 L-carnitine solution for direct infusion: from a 100 mM solution in H2O, 15 μL was mixed 136 
with 5 μL isopropanol in a 96 wells-plate to yield a final 75 mM L-carnitine solution. 137 
2.2.2 Urine sample preparations: a general metabolome extraction procedure was performed: i) 5 138 
µL urine was extracted in 200 µL chloroform/methanol/water (1:3:1) at 4 ˚C; ii) then vortexed for  5 139 
minutes at 4 ˚C; iii) then centrifuged for 3 minutes (13,000 g) at 4 ˚C. The resulting supernatant was 140 
stored at -80 ˚C until analysis. 141 
2.2.3 NanoMate direct infusion measurements: to allow for sufficient spray time for extensive 142 
fragmentation experiments, a chip-based nano electrospray (Triversa Nanomate, Advion, US) source 143 
was used in infusion mode with a set up as described previously (Van der Hooft et al., 2011). The 144 
key settings were: positive ionization mode, sample volume of 10 µL, a gas pressure of 0.5 psi, and a 145 
voltage of 1.5 kV, with a data acquisition delay of 0.5 minute. Orbitrap Elite FTMS mass 146 
spectrometry settings: AGC 1 × 10
6
 (full scan mode) and 5 × 10
4
 (MS
n
 mode), capillary temperature 147 
220 °C, source voltage +1.6 kV, source current 100 μA, S-lens RF 65.5%, skimmer offset 0 V, 1 148 
microscan, and the mass spectrometer was calibrated with Thermo calmix and tuned on m/z 195.10 149 
(caffeine). Full scan data was acquired for 1 minute to check signal intensity and purity of the 150 
sample. MS2 fragmentation spectra were obtained for 5 minutes in positive ionization mode using 151 
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CID and HCD fragmentation modes from 10 to 200 normalized collision energy (NCE), in steps of 152 
10 NCE. Further key settings were: isolation width of 3.0 Da, minimum signal required of 4500, first 153 
mass fixed at 50.00 m/z (HCD), and additional microscans and AGC targets were 2 and 0 (MS2), 4 154 
and 2 × 10
6
 (MS3), and 6 and 3 × 10
6
 (MS4), respectively. 155 
2.2.4 HILIC-MS/MS:  156 
The LC separation was performed using hydrophilic interaction chromatography (Creek et al., 2011), 157 
using the following equipment, gradients, and settings: 158 
i) ZIC-pHILIC 150 mm × 4.6 mm, 5 μm column (Merck Sequant) equipped with the 159 
corresponding pre-column, operated by an UltiMate 3000 RSLCnano liquid 160 
chromatography system (Dionex, Camberley, Surrey, UK). The LC mobile phase was a 161 
linear biphasic gradient from 80% B to 20% B over 15 min, followed by a 2 min wash 162 
with 5% B, and 8 min re-equilibration with 80% B, where solvent B is acetonitrile and 163 
solvent A is 20 mM ammonium carbonate in water. The flow rate was 300 μL/min, 164 
column temperature was held at 35 °C, injection volume was 10 μL, and samples were 165 
maintained at 4 °C in the autosampler. 166 
ii) ZIC-HILIC 150 mm × 2.1 mm, 3.5 μm column (Merck Sequant) equipped with the 167 
corresponding pre-column, operated by an UltiMate 3000 RSLCnano liquid 168 
chromatography system (Dionex, Camberley, Surrey). The LC mobile phase was a 169 
biphasic linear gradient from 80% B to 20% B over 30 min, followed by an 8 min wash 170 
with 5% B, and 8 min re-equilibration with 80% B, where solvent B is 0.08% formic acid 171 
in acetonitrile and solvent A is 0.1% formic acid in water. The flow rate was 100 μL/min, 172 
column temperature was held at 35 °C, injection volume was 10 μL, and samples were 173 
maintained at 4 °C in the autosampler. 174 
The Orbitrap Elite mass spectrometer was calibrated using Thermo calibration mix in positive 175 
ionization mode and tuned on m/z 195.10 (caffeine). Source mass spectrometry settings for both ZIC-176 
HILIC and ZIC-pHILIC  in positive ionization mode were as follows: a HESI 2 probe was used with 177 
AGC 1 × 10
6
 (full scan mode) and 5 × 10
4
 (MS
n
 mode), sheath gas 10 a.u., auxiliary gas 5 a.u., sweep 178 
gas 1 a.u., source heater temperature 150 °C, capillary temperature 275 °C, source voltage +4 kV, 179 
source current 100 μA, S-lens RF 50%, skimmer offset 0 V, maximum ion times of 100 ms (full scan 180 
mode) and 200 ms (MS
n
 mode), and all scans consist of 1 microscan. 181 
Data dependent ZIC-pHILIC-MS/MS and MS
n
: data was obtained in profile mode, for full scans the 182 
m/z window was 70.00 – 1000.00 and the resolution was set to 240,000. For fragmentation 183 
experiments, key settings were: isolation width of 1.0 Da, minimum signal required of 500, first mass 184 
fixed at 50.00 m/z (HCD), and a dynamic exclusion of 48 seconds. A rejection list was included with 185 
the top 15 most intense ions encountered in blank injections preceding the fragmentation runs to 186 
reduce the number of non-informative fragmentation spectra. HCD fragmentation spectra of the most 187 
intense ion (data dependent acquisition) in the full scan were obtained at 30, 70, and 110 normalized 188 
collision energies (NCE). CID-MS
n
 (n≤3) fragmentation was performed as in (Van der Hooft et al., 189 
2012b), but using 45 NCE. 190 
Data dependent ZIC-HILIC-MS/MS: as for ZIC-pHILIC-MS, with a resolution set to 120,000 for full 191 
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scan mode, and 15,000 for MS≥2. 192 
Targeted ZIC-HILIC-MS/MS: as for ZIC-HILIC-MS/MS, with a parent ion list including masses of 193 
potential acylcarnitine structures with retention times comparable to previously annotated 194 
acylcarnitine structures in the data dependent HILIC-MS/MS runs of urine 3 and 4, i.e., eluting 195 
between 5 and 7 minutes. The parent ion lists for urine extracts 5 – 7  included in total 27 masses not 196 
previously fragmented and annotated in urines 1-4 for which the most probable elemental formula 197 
matches CxHyNOz, i.e. comprising of one nitrogen atom and no other elements than carbon, hydrogen 198 
and oxygen. The structure of the MS/MS method was as follows: one full scan, followed by 199 
fragmentation at 30, 70, and 110 NCE of the two most intense ions present at the parent ion list (i.e., 200 
no fragmentation took place if no targeted ions were present above the threshold). 201 
Prior to the hyphenated MS fragmentation experiments, a series of 4 blanks, quality control samples, 202 
and standards mixtures were injected to stabilize the system, determine background ions for the 203 
rejection list in data dependent fragmentation, and check the quality of the chromatographic runs. 204 
Accurate masses of standards were obtained well within 5 ppm accuracy. 205 
2.3 Data analysis: 206 
Thermo raw data files were checked for the presence of informative fragmentation spectra in 207 
Xcalibur version 2.2. Raw data files were then converted into mzXML files (using 208 
MM_File_Conversion3, http://www.massmatrix.net/mm-cgi/downloads.py) prior to MAGMa 209 
analysis (www.emetabolomics.org) (Ridder et al., 2014b). The MzXML files are available to 210 
download in the supplementary information. 211 
2.3.1 MAGMa settings and analysis: 212 
The MzXML files were uploaded to the MAGMa server and MAGMa default settings were used to 213 
annotate urine data dependent fragmentation files with compounds present in HMDB (updated at 214 
April 2014), except for a maximum of 2 allowed water losses (in generated substructures by breaking 215 
up to 3 bonds) and minimum intensity threshold levels of 1500 counts, and 2% of the base peak for 216 
substructure annotation. This annotation is based on the detected precursor masses and the detected 217 
fragments, and produces proposed fragment annotations with a penalty score that determines the 218 
candidate scores and rankings of candidate metabolites (Ridder et al., 2012). CID (MS
n
) type of
 
files 219 
were handled as in (Ridder et al., 2014c). Multiple HCD-MS
2
 fragmentation spectra of the same 220 
precursor ion, recorded at the different collision energies, were merged by MAGMa as suggested 221 
previously (Horai et al., 2010;Wolf et al., 2010). Each analysis took three minutes or less. Annotated 222 
acylcarnitines and carnitine related compounds were extracted from all the MAGMa annotations in 223 
the results page by applying a filter on the metabolite names (‘carnitine’) in order to count the 224 
number of annotated acylcarnitines in each run. 225 
2.3.2 Acylcarnitine annotation using the mass fragmentation filter: 226 
To scan for compounds that fulfil the defined filter criteria, extracted ion chromatograms and neutral 227 
loss traces were created in Xcalibur from the raw data files with a 6 ppm window, to account for less 228 
accurate mass values in the lower m/z range of fragmentation spectra. 229 
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2.3.3 Metabolite annotation: 230 
Metabolites were classified as acylcarnitines if the most likely elemental formula matched the mass 231 
fragment and neutral loss filter as described in 2.3.2. It should be stressed that this study does not 232 
intend to fully identify the acylcarnitine molecules, but focuses instead on robust metabolite 233 
annotation of acylcarnitines by their classification whilst obtaining structural information on the acyl 234 
moiety (i.e., MSI Metabolite Identification (MSI MI) level 3 (Sumner et al., 2007;van der Hooft et 235 
al., 2013)). MSI MI level 2 can be achieved if the generated fragmentation pattern matched a spectral 236 
database spectrum. Full identification would be achievable by obtaining authentic standards or by 237 
elaborate concentration and purification from the urine matrix, but falls outside the scope of this 238 
study. Scifinder analyses (July 2014) were performed to obtain the number of candidates for i) the 239 
elemental formula, ii) the elemental formula refined with carnitine as substructure, and iii) the 240 
number of references for the most cited acylcarnitine structure in Scifinder. In addition, for each 241 
annotated acylcarnitine, the number of HCD fragments between m/z 85 and the fragmented precursor 242 
mass, the number of oxygen atoms in the acylcarnitine minus the 3 oxygen atoms in carnitine, and 243 
the C:H ratio for each annotated acylcarnitine was determined. Additionally, the presence of 244 
matching carnitine metabolites in HMDB was checked (Supplementary Table).  245 
The acyl moiety was annotated by searching for and matching of fragmentation spectra of 246 
acylcarnitine reference compounds in the following databases: METLIN (http://metlin.scripps.edu/), 247 
mzCloud (www.mzcloud.org), and HMDB (http:// http://www.hmdb.ca). Furthermore, the HMDB-248 
MAGMa annotation was studied, as well as the acyl derived mass fragments and neutral losses. The 249 
resulting metabolite annotations are listed in the Supplementary Table. 250 
 251 
  252 
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3. Results 253 
We employed a generic metabolite extraction method (Vincent and Barrett, 2014) with untargeted 254 
small metabolite pHILIC and HILIC profiling approaches (Creek et al., 2011;Zhang et al., 2012) in 255 
combination with HCD-MSMS and CID-MS
n
 fragmentation to determine whether robust metabolite 256 
annotation of small polar metabolites could be established using accurate mass fragmentation spectra. 257 
Both pHILIC and HILIC chromatography were included in the study to cover the two routinely used 258 
chromatographic separations in our laboratory. As a test case we have focused on seeking to enhance 259 
the annotation of acylcarnitines in the complex mixture human urine is. Since acylcarnitines poorly 260 
ionize in negative ionization mode, positive ionization mass spectrometry was employed. Two 261 
human urine extracts (urine extract 1 and 2) were run using the same pHILIC chromatography, but 262 
differing in HCD or CID (MS
n
) type fragmentation as specified in the methods section 2.2.4.  263 
3.1 MAGMa annotation with HMDB candidates of untargeted analysis of two urine extracts  264 
From the MzXML files of human urine 1, 615 merged HCD-MS2 and 461 CID-MSn spectra were 265 
read by MAGMa (Ridder et al., 2014c), for HCD and CID types of fragmentation, respectively. A 266 
total of 413 and 372 candidates from HMDB (Wishart et al., 2013), including both known molecules 267 
as well as structures predicted to be present in human samples, were matched to 292 and 224 268 
precursor ions, respectively.  Supported by the substructure based interpretation of fragment spectra 269 
in MAGMa, the annotation of a range of urine metabolites could be confirmed. For example, 4-270 
guanidinobutanoic acid (HMDB03464) and guanidoacetic acid (HMDB00128) were annotated to a 271 
fragmented LC-MS peak, both containing a mass fragment that indicates the presence of a guanido 272 
group. Those acids are known to be present in human urine. Homocarnosine (HMDB00745) is 273 
another MAGMa annotated compound found in urine. Interestingly, by using MAGMa we also 274 
annotated acetylcarnosine (HMDB12881), a compound predicted to be present in human samples, 275 
but not previously observed or confidently annotated. The dipeptide prolylhydroxyproline 276 
(HMDB06695) was annotated based on its precursor peak and mass fragments, including two 277 
hydroxyproline fragments ([C5H8NO3]
+
 and [C4H6N]
+
), providing evidence for the 278 
prolylhydroxyproline configuration over the hydroxylprolyl dipeptide. Similarly, four predicted 279 
isoleucine/leucine containing dipeptides were annotated, including the isomers alanyl-isoleucine 280 
(HMDB28690) and isoleucyl-alanine (HMDB28900) or their leucine analogues. 281 
Glycerophosphocholine (HMDB00086) was present as a lower abundant peak in the mass 282 
chromatogram, showing distinct fragments for its phosphor-containing fragments. Finally, the 283 
annotated L-carnitine (HMDB00062) was one of the major abundant peaks in the chromatogram.  284 
It should be further noted that 323 and 332 HCD precursors, and 237 and 245 CID precursors, for 285 
urine 1 and 2 respectively, did not match any candidate from HMDB.Currently, the online HMDB 286 
database contains 69 carnitine related metabolites, of which 36 are described to be present in human 287 
samples, the remainder being predicted to be present in humans. The MAGMa metabolite annotation 288 
of HMDB compounds to the HCD and CID fragmentation files of urines 1 and 2 resulted in 12 289 
annotated acylcarnitine candidates, of which 3 had one or multiple isomers matched. These 290 
candidates included carnitine (HMDB00062) and 3-dehydrocarnitine (HMDB12154). Not all 291 
acylcarnitines were annotated in those four fragmentation files due to i) the stochastic nature of the 292 
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data dependent fragmentation, omitting the fragmentation of the mass features annotated with 293 
propionylcarnitine (HMDB00824) and tiglylcarnitine (HMDB02366) in the CID fragmentation file 294 
of urine 2, and ii) the biological differences between the two urine files, resulting in different 295 
abundance levels for three annotated acylcarnitines. For example, 2-trans,4-cis-decadienoylcarnitine 296 
(HMDB13325) was three times more abundant in human urine 1 (1.1E6 vs 3.3E5 cts), triggering data 297 
dependent fragmentation in human urine 1, but not in human urine 2. We note that CID and HCD 298 
fragmentation types were equally informative with respect to HMDB acylcarnitine annotations with 299 
MAGMa. Moreover, no other type of structures from HMDB was matched to the annotated 300 
acylcarnitine fragmentation spectra. 301 
 302 
3.2 MAGMa analysis of pHILIC runs for fragment annotation and construction of a mass 303 
fragmentation filter to classify acylcarnitines 304 
In order to determine key fragments or neutral losses (or a combination thereof) that can be used to 305 
screen for acylcarnitines, the fragment annotations as proposed by MAGMa were studied. Figure 2A 306 
shows a screenshot of the fragment list of the HMDB-annotated tiglylcarnitine (fragments ≥ m/z 85) 307 
using HCD type of fragmentation spectra as input. Fragments that yield structural information from 308 
the entire carnitine moiety would offer an ideal means to classify fragmented acylcarnitine species as 309 
it is common to all members of the class. As can be seen in Figure 2A, a combination of the mass 310 
fragment [C4H5O2]
+
 and a neutral loss of C3H9N (i.e., trimethylamine), covers the entire carnitine 311 
molecule, whereas larger carnitine-related fragments, i.e., dehydrated carnitine, are absent or of low 312 
abundance in the fragmentation spectrum (Figure 2B). Moreover, the mass fragment [C4H5O2]
+
 and 313 
neutral loss C3H9N are the two most intense features of the spectrum. Further inspection of merged 314 
HCD spectra of annotated acylcarnitines in MAGMa showed the fragment [C4H5O2]
+
 and neutral loss 315 
C3H9N to be present in all merged fragmentation spectra, indicating a combination of those two can 316 
be used for acylcarnitine classification. The fragment annotation as proposed by MAGMa for 317 
acylcarnitines was also compared to literature postulations (Yang et al., 2007; Zuniga and Li, 2011) 318 
and found to be consistent. 319 
Using CID fragmentation, the mass fragment [C4H5O2]
+
 and the neutral loss C3H9N both occur, as 320 
can be seen in Figure 3 for one annotated acylcarnitine; however, the mass fragment [C4H5O2]
+
 is 321 
obtained with 5-fold lower intensities compared to HCD fragmentation, whereas the neutral loss 322 
occurs at similar abundance. Moreover, most of the MS3 scans obtained in CID-MS
n
 did not provide 323 
additional fragment information, being empty or repeating the MS2 fragment [C4H5O2]
+
 as in Figure 324 
3B. Thus, based on the comparison of CID-MS
n
 and HCD-MS2 type of fragmentation for 325 
acylcarnitines, the HCD-MS2 fragmentation was found to be the preferred fragmentation type to 326 
classify and annotate this class of compounds. Therefore, the remainder of the study is mostly based 327 
on HCD fragmentation. 328 
Figure 4 shows the CID-MS
2
 and HCD-MS
2
 spectra of L-carnitine obtained by direct infusion of the 329 
reference compound (see Methods section 2.2.3), confirming the presence of the mass fragment 330 
[C4H5O2]
+
 and the neutral loss C3H9N (resulting in C4H7O3; m/z 103.0390) upon carnitine 331 
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fragmentation. As in the LC-MS experiments, the abundance of the key mass fragment is much lower 332 
for the displayed CID-MS
2
 fragmentation spectrum, supporting HCD as the preferred fragmentation 333 
type to classify and annotate acylcarnitines. Based on the LC-MS and direct infusion experiments, we 334 
concluded that in the case of HCD type fragmentation, a mass fragmentation filter of the fragment 335 
mass [C4H5O2]
+
 (m/z 85.0284) and a neutral loss of C3H9N (m/z 59.0735) can be used to annotate 336 
acylcarnitines; in case of CID-MS
n
, the same filter could be applied (valid for acylcarnitines up to 337 
357 m/z due to the 1/3 cut-off rule as a result of the Ion trap configuration), but it would work less 338 
well for lower abundant acylcarnitines. 339 
 340 
3.3 HCD-MS
2
 fragmentation spectra: different collision energies are required to obtain 341 
sufficient structural information for classification and further annotation of the acyl moiety 342 
Low fragmentation energies usually result in the loss of the more labile side groups of metabolites, 343 
such as a carboxyl or hydroxyl group, whereas higher collision energies tend to break up molecular 344 
structures into smaller, energetically stable fragments (Watson and Sparkman, 2007). Therefore, the 345 
probability of finding a unique combination of fragments or neutral losses for a specific metabolite 346 
class increases if multiple fragmentation energies are used. Moreover, it is likely that more structural 347 
information can be obtained from a combination of different collisional energies. 348 
Figure 6 shows the low (A), middle (B), and high (C) energy HCD-MS
2
 fragmentation spectra for a 349 
novel acylcarnitine structure (i.e., not present in Scifinder) that was detected and annotated in this 350 
study. The three spectra are clearly different with the neutral loss from the carnitine substructure 351 
present in the low energy spectrum, but not observed at higher energies. In contrast, the key fragment 352 
C4H5O2 observed at low abundance in Figure 6A is the base peak in the middle and higher collision 353 
energy spectra (Figures 6B and 6C). The different energies show complementary fragments derived 354 
from the acyl part of the acylcarnitine molecule, which assists in further structural characterization. 355 
This use of three HCD-MS
2
 fragmentation energies resulted in complementary structural information 356 
and enabled detection of both the key neutral loss and fragment that together form the acylcarnitine 357 
mass fragmentation filter as well as the detection of structurally informative acyl derived fragments. 358 
 359 
3.4 Application of the mass fragment and neutral loss filter to classify fragmented 360 
acylcarnitines in pHILIC-MS and HILIC-MS data dependent fragmentation runs 361 
  362 
The initial MAGMa analysis enabled the annotation of the LC-MS/MS files with candidate 363 
acylcarnitine structures from HMDB and the design of a mass fragmentation filter to classify 364 
acylcarnitines based on the proposed substructure annotations. Subsequently, this filter was applied 365 
to the data dependent (information dependent, untargeted) HCD fragmentation data of the two urine 366 
extracts run with pHILIC gradients (urine 1 and 2), and two urine extracts run with a HILIC-MS/MS 367 
gradient (urine 3 and 4). This led to the classification of 22 different acylcarnitines including 368 
carnitine itself, 10 of which occurred as multiple isomers, based on concurrence of the key neutral 369 
loss and the key fragment in the MS
2
 fragmentation spectra of detected and fragmented acylcarnitine 370 
species. Dehydrocarnitine does not display the typical fragmentation as observed for carnitine and 371 
was therefore not classified. The classified acylcarnitines ranged from m/z 162.1125 ([M+H]
+
), 372 
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identified as carnitine, to m/z 318.1911 ([M+H]
+
), annotated as the conjugate of suberic acid (octane-373 
1,8-dioic acid) and carnitine (MSI MI level 3). Notably, out of the 22 annotated acylcarnitines, 11 374 
were not present in HMDB and were thus previously not annotated with MAGMa. Furthermore, one 375 
candidate acylcarnitine structure is present in HMDB for four annotated acylcarnitine isomer pairs. 376 
 377 
3.5 Application of mass fragment and neutral loss filter on targeted fragmentation spectra of 378 
suspected low abundant acylcarnitine species detected during untargeted metabolomics. 379 
Upon studying full scan HILIC-MS data of extracts 5, 6, and 7 of human urines, 27 masses of 380 
potential lower abundant acylcarnitine structures not previously fragmented and annotated in urines 1 381 
- 4 were included in parent ion lists (see section 2.2.4). Based on the resulting HCD fragmentations 382 
that could be obtained in sufficient quality for 19 of them, 18 masses were confirmed to be 383 
acylcarnitines. Most of these acylcarnitines had higher m/z values, i.e., >330 Da, than those 384 
annotated during the data dependent fragmentation runs. An exception is the acylcarnitine with 385 
elemental formula C13H20NO6 ([M+H]
+
, m/z 286.1285), which could be annotated as a conjugate of 386 
C6H6O4 (possibly 2-furyl(hydroxy)acetic acid or 2,3-methylenesuccinic acid) and carnitine (MSI MI 387 
level 3).  388 
3.6 Scifinder analysis of annotated acylcarnitines 389 
Scifinder, a widely used, comprehensive, and well-curated compound database, was used to evaluate 390 
the present findings (https://scifinder.cas.org/scifinder). All annotated acylcarnitine formulae were 391 
searched in Scifinder, returning ‘all hits’, i.e., all by Scifinder known structures with that elemental 392 
formula. Subsequently, the refine panel in Scifinder was used and a substructure search based on the 393 
carnitine structure was performed within all the hits for a given elemental formula, returning 394 
‘carnitine refined hits’. Finally, if one or more acylcarnitine structures were returned by Scifinder, the 395 
number of ‘references to the top hit’ was noted as an indication of how well-known the structure is. 396 
Figure 5 shows histograms of the Scifinder analysis for all 50 annotated acylcarnitines, including 397 
those annotated using data dependent fragmentation (22), those annotated using a parent ion list (18), 398 
and the annotated acylcarnitine isomers (10). Detailed figures can be found in the Supporting Table.  399 
 400 
Of the 22 acylcarnitines annotated using data from untargeted fragmentation, 12 had more than 10 401 
references for the most cited acylcarnitine structure in Scifinder, indicating that they are relatively 402 
well-studied and characterized. However, accurate mass fragmentation spectra of underivatized 403 
forms of these acylcarnitines are still sparse, since the acylcarnitines were identified in the references 404 
based on either GC-MS or LC-MS data combined with nominal mass fragmentation. Moreover, 7 of 405 
the 22 elemental formulae resulted in 2 or less references for the most cited acylcarnitine structure in 406 
Scifinder. For example, no acylcarnitine structure with elemental formula C12H18NO5 ([M+H]
+
, m/z 407 
256.1179) was present in Scifinder. The corresponding acyl-moiety with elemental formula C5H4O3 408 
could match four possible structures in HMDB, with 3-furoic acid (HMDB 004444) being a likely 409 
candidate based on natural abundance in human urine. However, the HCD spectrum does not indicate 410 
the presence of a furan moiety, nor any other fragment to allow confirmation of one of the candidate 411 
acyl structures. Of the acylcarnitines annotated using a parent ion list, seven did not yield any hits in 412 
Scifinder with their elemental formula and substructure refinement as input (Supplementary Table). 413 
Last Name author1 et al.  Running Title 
 12 This is a provisional file, not the final typeset article 
This shows that targeted (data independent) fragmentation data in combination with a mass 414 
fragmentation filter can be used to structurally classify observed mass peaks in untargeted mass 415 
spectrometry experiments.  416 
Taken all 50 annotated acylcarnitines together, half of them have 5 or less references for the most 417 
cited acylcarnitine structure, indicating that few studies could reliably annotate or identify these 418 
acylcarnitines. This Scifinder analysis shows that the presented workflow yields new knowledge 419 
from untargeted metabolomics experiments by generating data dependent accurate mass 420 
fragmentation data and providing robust classification of acylcarnitine species both present and 421 
absent in HMDB. 422 
 423 
3.7 Structural annotation of the acyl moiety 424 
After classification of an acylcarnitine (MSI MI level 3), more information on the fragmented 425 
metabolites can be obtained by comparison of the obtained fragmentation spectra with database 426 
spectra (if present, MSI MI level 2) or studying the fragments derived from the acyl part. The 427 
fragmentation data was analyzed as described in section 2.3.3. This resulted in 3 MSI level 2 428 
annotations for acylcarnitines and their fragmentation data present in MzCloud or Metlin. In addition, 429 
DL-carnitine could be annotated with MSI MI level 1, since the fragmentation spectrum of the 430 
urinary compound matched with that of an authentic standard. Accurate mass fragmentation data for 431 
the remaining 46 acylcarnitines could not be found; therefore, acyl-derived mass fragments and 432 
neutral losses (from the suspected acyl-parent ion) were studied.  For example, double CH2O2 and/or 433 
H2O loss appeared to be indicative for a di-carboxylated acyl moiety, like suberic acid and 434 
dodecanedioic acid. To explore another route to structural annotation of the acyl moiety, acyl-derived 435 
fragments were manually uploaded into MAGMa to find candidate acyl-structures. All annotations of 436 
the studied acylcarnitines can be found in the Supplementary Table. 437 
 438 
Three cases are described here in more detail. As described in section 3.4, Figure 6 shows the 439 
fragmentation spectra of an acylcarnitine with elemental formula C16H30NO6 ([M+H]
+
, m/z 440 
316.2118). Its acyl part is represented by several fragments at lower fragmentation energy, the largest 441 
being C9H17O3. Neutral losses of H2O and CH2O2 from this fragment indicate the presence of a 442 
carboxyl group within the acyl moiety. In order to obtain candidate structures for the acyl moiety 443 
based on the observed fragments, a list of acyl-derived fragment masses and the suspected ‘parent 444 
mass’ was uploaded into MAGMa, and HMDB and Pubchem were queried using default MAGMa 445 
parameters. The nine resulting HMDB candidates all had the elemental formula of C9H16O3 but none 446 
had a free carboxyl group. Pubchem resulted in 2,158 candidates (all C9H16O3), with four 447 
hydroxylated C9:1-fatty acids among the top 35 metabolites (based on candidate scores). Thus, the 448 
C16H30NO6 ([M+H]
+
 acylcarnitine could be annotated as a C9:1-OH-acylcarntine (MSI MI level 3).  449 
 450 
Figure 7 shows the spectra of the annotated acylcarnitine with elemental formula C21H36NO5 451 
([M+H]
+
, m/z 382.2588),which represents a C14H22O3-carnitine conjugate. The mass fragments and 452 
losses present at lower and higher energies, i.e., the combined loss of C2H6O3 and the mass fragments 453 
C12H17 and C9H11 ([Molecular Fragment (MF)]
+
), revealed no indicative losses of a carboxyl group. 454 
The acyl moiety likely consists of a branched, unsaturated alkyl chain, since the ring double bond 455 
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equivalent of C14H22O3 is 4. The acyl-derived fragment masses and suspected parent mass were 456 
queried, and HMDB returned one metabolite, geranyl acetoacetate, with the correct elemental 457 
formula; however, two fragments, C13H19 and C12H17 ([MF]
+
), could not be explained by MAGMa 458 
based on this structure, and many others had a high penalty score (≥5). Pubchem, however, returned 459 
1,743 candidate structures with the elemental formula C14H22O3, of which a 3-hydroxytetradeca-460 
5,8,11-trienoic acid, was listed in the top 5 (based on candidate scores), and appears to be a plausible 461 
candidate. Therefore, this acylcarnitine could be annotated as a C14:3-OH-acylcarnitine (MSI MI 462 
level 3). Interestingly, several of the observed fragments in Figure 6A and 6B (i.e., C7H7, m/z 463 
91.0542; C7H9, m/z 93.0699; and C7H11, m/z 95.0855, all [MF]
+
) were also found in other high mass 464 
acylcarnitines (i.e., > 330 m/z) at higher collision energies, indicating similar substructures in the 465 
acyl moiety of these metabolites. 466 
 467 
Figure 8 shows the fragmentation spectra of a novel detected acylcarnitine (i.e., not present in 468 
Scifinder) with the elemental formula C17H26NO6 ([M+H]
+
 and m/z 340.1755, which shows mass 469 
fragments different from most other acylcarnitine spectra observed in this study. Its conjugated acyl 470 
moiety has the elemental formula of C10H12O4 (which implies five ring double bond equivalents), 471 
likely to be caused by the presence of an aromatic ring. Further evidence is provided by the 472 
fragments C6H7 and C5H6 [MF]
+
. A (radical) loss of CH3 was also observed, indicating a methoxy 473 
substitution on the aromatic ring. After collecting the acyl-derived fragment masses and suspected 474 
parent mass, HMDB returned 13 candidates with the elemental formula C10H12O4, of which 2-475 
hydroxy-3-(4-methoxyphenyl)propanoic acid is a potential candidate. However, the fragment C7H6O2 476 
(m/z 122.0361 [MF]
+
) does not fit well within the structure without breaking the aromatic ring. 477 
Pubchem yielded 1,520 candidates based on the input mass fragments, all with elemental formula 478 
C10H12O4. Within the top 20 hits (based on candidate scores), dihydroferulic acid and five structurally 479 
related isomers were present candidate structures for the acyl moiety. The fragment C7H6O2 [MF]
+ 480 
can be explained with an intact aromatic ring, indicating that the hydroxyl group is substituted to the 481 
aromatic ring. Altogether, this acylcarnitine could be annotated as conjugate of carnitine and 482 
C10H12O4, with a likely candidate being 3-(4-hydroxy-3-methoxyphenyl)propionic acid (i.e., 483 
dihydroferulic acid) or a structurally related isomer (MSI MI level 3). 484 
  485 
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4. Discussion 486 
This study explored the use of accurate mass fragmentation approaches in untargeted and targeted 487 
HILIC-MS metabolomics experiments to obtain increased confidence in metabolite annotations. 488 
Human urine extracts, representing a complex mixture of metabolites offered a good test case. 489 
Acylcarnitines, metabolites involved in energy metabolism (Frayn, 2010) are relatively abundant in 490 
urine and identified as biomarkers for various related diseases (Adams et al., 2009;Patterson et al., 491 
2009;Luan et al., 2014). Initial metabolite annotation of candidate metabolites present in HMDB 492 
resulted in the matching of 12 candidate acylcarnitines to fragmentation data files using the MAGMa 493 
interface (Ridder et al., 2014c). These annotations then allowed us to define a mass fragment and 494 
neutral loss filter to classify detected and fragmented acylcarnitines from standard pHILIC and 495 
HILIC LC-MS runs of urine extracts. With the use of this filter in the context of an untargeted 496 
metabolomics experiment, substantially more acylcarnitines could be reliably annotated from each 497 
run, yielding a total of 50 uniquely classified acylcarnitine species (including multiple observed 498 
isomers) in both untargeted (32) and targeted (18) fragmentation runs studied (MSI MI level 3). 499 
Using our metabolomics platform, these confident annotations were previously not possible; 500 
however, using the methodology described in this study, we could enhance the annotation power of 501 
our platform for acylcarnitines, and at the same time collect novel accurate mass fragmentation data 502 
for this set of acylcarnitines. 503 
Previous work showed the value of parent and neutral loss monitoring in a quadrupole ion trap for 504 
targeted screening of acylcarnitines in biological samples (McClellan et al., 2002;Shigematsu et al., 505 
2002;Paglia et al., 2008;Rinaldo et al., 2008). In addition, several studies applied multiple reaction 506 
monitoring (MRM) type of approaches using the 85 m/z nominal mass fragment or the neutral loss of 507 
60 to target specifically for acylcarnitines (Maeda et al., 2008;Kivilompolo et al., 2013;Peng et al., 508 
2013b) or specific derivatization to probe for acylcarnitines (Minkler et al., 2005). It should be noted 509 
that all the above mentioned targeted approaches required dedicated sample preparation, used 510 
nominal mass spectrometers, and in many cases applied derivatization to enhance the sensitivity of 511 
the method. Our study showed that the use of such parent and neutral loss monitoring within the 512 
context of untargeted high-resolution metabolomics experiments is very valuable in enabling robust 513 
annotations for a biologically relevant class of metabolites without the use of specific sample 514 
extractions, chromatographic gradients, or complex MRM methods. 515 
Zuniga and Li reported the most comprehensive study up to now using a similar, but nominal, mass 516 
filter for acylcarnitine detection, and reported 355 acylcarnitine species (non-derivatized) in a 2-hours 517 
UPLC gradient (Zuniga and Li, 2011). Unfortunately, these are not yet included in the HMDB 518 
database, and 16 out of the 355 substances reported in the study were added to Scifinder. A possible 519 
reason could be that no definite elemental formulas were assigned to all reported acylcarnitines, 520 
because the annotations were done on the basis of nominal mass spectra and postulated fragment 521 
structures. In contrast, our approach could provide more confident annotations based on the accurate 522 
mass full scan and MS
2
 fragmentation spectra, allowing confident elemental formula assignments 523 
and classification as acylcarnitines, as was very recently underlined by Sumner et al. (Sumner et al., 524 
2014). Comparison of our data to the spectra obtained by Zuniga and Li was done, and for the three 525 
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presented cases in Figure 6 – 8, the most likely corresponding acylcarnitines, as monitored and 526 
labelled with their nominal observed mass and isomer letter in their supporting information by 527 
Zuniga and Li, are 316[E] (fragment 127.1), 382[C] (fragments 161.3, 119.2, 95.1 and 91.0), and 528 
340[A+B] (fragments 179.2 and 137.0) for annotated acylcarnitines in Figure 6, 7, and 8 respectively 529 
(with corresponding fragments to our study between brackets). It should be noted that the 2-hours 530 
UPLC gradient allowed for separation of structurally related acylcarnitines that were not separated in 531 
our 15 (pHILIC) and 30 (HILIC) minutes gradient. All annotated masses in this study could 532 
potentially be matched with nominal masses found in Zuniga and Li’s extensive study, but a detailed 533 
comparison for all annotated acylcarnitines is hampered by differences in chromatography and mass 534 
spectrometry methodology used.An advantage of our approach is the use of multiple fragmentation 535 
energies resulting in both higher-mass fragments (at low collision energy) and lower-mass fragments 536 
(at high collision energy), creating a unique fingerprint and enabling further structural 537 
characterization of the acyl moiety than in previous studies. The combination of multiple energies 538 
also allowed more fragments to be detected; and the number of fragment increased with increasing 539 
molecular mass (Figure 9). The number of fragments has a great impact on the structural information 540 
that can be gathered from a fragmentation spectrum. It should be added that annotated isomeric 541 
acylcarnitines generated similar fragmentation spectra (see also section 4.3). Remarkably, 27 unique 542 
acylcarnitine elemental formulas returned no hits upon querying in HMDB; indicating the need for 543 
improving database coverage to facilitate metabolite annotations (see section 4.4). Therefore, 544 
alternative ways to characterize the structure of the acyl moiety were explored in this study. We 545 
compared fragmentation spectra to spectral databases and by studying neutral losses and using 546 
MAGMa to find candidate metabolites (see section 3.6), thereby revealing the unexpected acyl 547 
moiety dihydroferulic acid or a structurally related isomer for one of the annotated acylcarnitines 548 
(Supplementary Table).  549 
 550 
4.1 Advantages of using MAGMa for initial annotation of urine extracts with HDMB 551 
candidates 552 
 MAGMa annotation of the LC-MS fragmentation data with candidates from an appropriate 553 
database (in this study HMDB (Wishart et al., 2013)), provided a quick overview of a diverse 554 
range of candidate metabolites present in the urine extracts.  555 
 The fragment annotations proposed by MAGMa helped to quickly recognize specific 556 
fragmentations of acylcarnitines. 557 
 558 
4.2 Advantages of using an accurate mass fragmentation filter to classify compounds within the 559 
context of untargeted metabolomics experiments 560 
 Measurement of fragmentation data in untargeted metabolite profiling experiments allows 561 
MSI MI level 3, and sometimes 2, annotations where otherwise only level 4 would be 562 
possible. A similar trend was previously observed for CID-MS
n
 approaches applied to plant 563 
secondary metabolites (Van der Hooft et al., 2012b). 564 
 Accurate fragment mass values allow more reliable elemental formula assignments of the 565 
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fragment ions and molecular ions, resulting in more reliable metabolite annotations (Sumner 566 
et al., 2014).  567 
 Acylcarnitines were reliably annotated in urine datasets that also contain fragmentation data 568 
of many other metabolite classes like amino acids and purines. This allows different classes 569 
of metabolites to be studied in the same datasets using the same approach. 570 
 571 
4.3 Limitations of the current study 572 
 Sample preparation and chromatography used were generic and not optimized for 573 
acylcarnitine detection, resulting in a lesser chromatographic resolution for acylcarnitines 574 
than obtained in some other others targeting acylcarnitines, e.g. (Gucciardi et al., 2012), 575 
(Zuniga and Li, 2011).  576 
 The data-dependent fragmentation approach in combination with the mass fragmentation 577 
filter did not result in annotation of all studied acylcarnitines, as for 18 lower abundant 578 
acylcarnitines a targeted fragmentation approach was needed to obtain fragmentation spectra 579 
enabling their classification as acylcarnitines.   580 
 Chromatographically separated, isomeric acylcarnitines (sharing the same elemental formula) 581 
could not be discriminated based on their fragmentation patterns and need additional spectral 582 
information (e.g. NMR spectroscopy) to confidently discriminate them. This phenomenon is 583 
commonly observed in mass spectrometry data, especially for stereoisomers, with some 584 
exceptions to this rule (Van der Hooft et al., 2011).   585 
 586 
4.4 Compound and spectral databases for metabolite annotation 587 
Our metabolite annotation would benefit from an increased coverage in compound databases (like 588 
HMDB) and spectral databases (like mzCloud, Metlin, and MassBank). The availability of more 589 
fragmentation spectra of reference compounds would facilitate the design of more mass 590 
fragmentation filters such as the one described in our study. Despite the fact that the MzCloud 591 
database (www.mzcloud.org) and Massbank (http://www.massbank.jp/) provide fragmentation data 592 
for many reference compounds, often in both ionization modes, at different energies, and from 593 
different instruments, MzCloud and Massbank contain spectral data for only 5 and 7 acylcarnitine 594 
structures, respectively, which is a small number compared to the 50 annotated in our study. In fact, 595 
in our study, only 3 of the reported acylcarnitines could be matched to database fragmentation spectra 596 
searched for in different spectral databases, ‘upgrading’ the level 3 annotation to level 2, apart from 597 
carnitine, for which we could obtain in-house reference data allowing for a MSI MI level 1 598 
identification. We also applied LipidSearch (ThermoScientific software) to our fragmentation data, 599 
but the software did not return any acylcarnitine candidates matched to the fragmentation data. 600 
Furthermore, as mentioned before, HMDB does not cover the majority of acylcarnitine elemental 601 
formulas annotated in this study. Emerging metabolite annotation software tools like MAGMa will 602 
benefit from an increased coverage of compound databases such as HMDB since they serve as input 603 
for candidate metabolites. Finally, standardization of metabolomics data reporting, as promoted by 604 
COSMOS (http://cosmos-fp7.eu/) and MetaboLights and the MSI initiative (Sumner et al., 605 
2007;Salek et al., 2013a;Salek et al., 2013b;Sumner et al., 2014) will allow metabolomics researchers 606 
to i) build on each other’s findings in method development and data analysis by easier exchange of 607 
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data and protocols, and ii) facilitate the search for earlier reported annotated metabolites and their 608 
spectral data, thereby facilitating metabolite annotations of present and future studies. 609 
4.5 Future research directions 610 
Implementation of mass fragmentation approaches into routine untargeted high-resolution 611 
metabolomics experiments would benefit from: i) finding a working compromise for the coverage of 612 
uniquely fragmented metabolites and the need for multiple energies or fragmentation depths (and 613 
thus scan cycle times); and ii) creating more mass fragmentation filters to classify metabolite features 614 
and support robust metabolite annotation, thereby reducing the number of MSI MI level 4 615 
annotations in untargeted metabolomics experiments: 616 
i) Data dependent fragmentation is a stochastic process resulting in mass peaks to be 617 
fragmented in one run and not in another. The use of different collision energies for HCD 618 
fragmentation proved to be essential to get as much structural information as possible on 619 
the annotated acylcarnitines (see section 3.3), and is important in untargeted mass 620 
spectrometry to get structural information on diverse set of compounds present in 621 
biological extracts (Madala et al., 2012). There is a compromise between the number of 622 
compounds for which fragmentation data can be acquired and the amount of fragment 623 
data generated per compound. Very recently, several ways to improve coverage of 624 
fragmented masses during data dependent analysis have been postulated, i.e., by using 625 
gas-phase fractionation (Calderón-Santiago et al., 2014), by so-called SWATH analysis 626 
(Roemmelt et al., 2014) through ‘delayed fragmentation’ as was proposed for peptide 627 
fragmentation in proteomics (Savitski et al., 2011), or by a combination of data dependent 628 
and independent fragmentation approaches (Hoffmann et al., 2014). It should be noted 629 
that some of those fragmentation strategies require sophisticated tools to analyze the 630 
resulting data sets as a result of multiple precursor ions being simultaneously fragmented. 631 
Therefore, extension of this work will be primarily focused on finding the optimal 632 
compromise between metabolite coverage and structural information using narrow 633 
isolation windows. 634 
ii) The present findings showed that metabolite classification (i.e., fatty acids, imidazole-635 
containing, carnitine–related, etc.) based on key mass fragments and neutral losses is a 636 
promising approach within the context of untargeted mass spectrometry. Moreover, the 637 
approach not only enables more complete annotations within complex metabolomics 638 
datasets; it also reduces the number of candidate metabolites to be considered for a 639 
detected mass feature, e.g., based on database queries on elemental formula, from more 640 
than 100 to only a handful (see Figure 5 and the Supplementary Table). Organic 641 
molecules consist of recurring subunits, often decorated with different side groups and 642 
chains. Therefore, future work will aim to derive more relevant structural key mass 643 
fragments and neutral losses for other classes of compounds present in complex biological 644 
samples, like human urine, by integrating expert knowledge and automated approaches. 645 
 646 
4.6 Conclusions 647 
Metabolite classification based on a specific set of observed fragments and neutral losses proved to 648 
be a successful approach in enabling robust annotations of mass peaks observed in untargeted mass 649 
spectrometry. MAGMa can successfully annotate acylcarnitine structures present in HMDB to 650 
fragmented acylcarnitine masses in complex biological samples. Based on the acylcarnitine CID and 651 
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HCD fragment and neutral loss annotation, a selective mass fragmentation filter was constructed. 652 
Application of that filter to HCD fragmentation data obtained using data dependent and targeted 653 
fragmentation methods led to the annotation of 50 urinary acylcarnitines of which most had not been 654 
reliably annotated before using a high-resolution HILIC-MS approach. The annotation approach we 655 
describe shows that within the context of untargeted high-resolution mass spectrometry based 656 
metabolomics experiments, reliable metabolite annotations can be achieved using standard, high-657 
throughput untargeted approaches in combination with mass fragmentation filters that allow for 658 
metabolite classifications.  659 
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Figure legends 839 
Figures/Tables: 840 
Figure 1: Graphical representation of the described data analysis approach, starting from top left 841 
following the arrows to the bottom right: untargeted mass chromatogram, fragmentation data 842 
acquisition, HMDB annotation and fragment annotation in MAGMa to find specific mass fragments 843 
and neutral losses for acylcarnitines, mass fragmentation filter and the structure of carnitine, 844 
extracted ion chromatogram and neutral loss trace for the acylcarnitine filter, extracted ion 845 
chromatogram and spectrum for a detected acylcarnitine, and an example acylcarnitine (conjugate of 846 
sebabic acid).  847 
Figure 2: A) Fragment annotation of HMDB-annotated acylcarnitine with elemental formula 848 
C12H21NO4 in MAGMa, annotated as tiglylcarnitine (HMDB02366), and B) merged HCD-MS
2
 849 
spectrum of  the annotated tiglylcarnitine. Arrows indicate the corresponding mass fragmentation 850 
peaks of the neutral loss of trimethylamine (yellow dashed arrow indicates neutral loss in the mass 851 
spectrum; the yellow full arrow points to resulting mass fragment) and of the mass fragment C4H5O2 852 
(blue full arrow).  853 
Figure 3: MAGMa screenshot of CID-MS
2
 spectrum (A) and CID-MS
3
 spectrum (B) of HMDB-854 
annotated tiglylcarnitine. The MS
3
 scan originates from the highest abundant MS
2
 ion. An arrow 855 
indicates the neutral loss of C3H9N, whereas a box captures the C4H5O2 fragment.  856 
Figure 4: Direct infusion MS/MS data of L-carnitine in CID (top) and HCD (bottom) mode in the 857 
m/z range 50 - 175. Both energies (CID@40NCE and HCD@90NCE) represent collision energies 858 
where the key fragment C4H5O2, marked with a blue oval, is an abundant ion in the respective 859 
fragmentation spectra. The yellow dashed arrow indicates the neutral loss of C3H9N. Boxes indicate 860 
where the fragmentation took place in a schematic representation of the hybrid mass spectrometer. 861 
Figure 5: Combined bar plot of the number of annotated acylcarnitine formulae for: i) ‘All hits’, i.e., 862 
the number of Scifinder hits for elemental formulas (EF) of the 50 annotated acylcarnitine formulae, 863 
Last Name author1 et al.  Running Title 
 24 This is a provisional file, not the final typeset article 
ii) ‘Carnitine refined hits’, i.e., the number of Scifinder hits with the refinement of a carnitine 864 
substructure, and iii) ‘References top hit’, i.e., the number of references to the most cited 865 
acylcarnitine (top hit). 866 
Figure 6: HCD type MS
2
 fragmentation spectra obtained at low (30NCE, A), middle (70NCE, B), 867 
and high (110NCE, C) energy for precursor mass 316.2118 m/z, with the proposed elemental formula 868 
of C16H29NO5. The key fragment C4H5O2, marked with a dashed oval, and the neutral loss C3H9N, 869 
indicated by a dashed arrow, occur in the spectra, and this fragmented metabolite could be annotated 870 
as an acylcarnitine. 871 
Figure 7: HCD type MS
2
 fragmentation spectra obtained at low (30NCE, A), middle (70NCE, B), 872 
and high (110NCE, C) energy for precursor mass 382.2588 m/z, with the proposed elemental formula 873 
of C21H35NO5. The key fragment C4H5O2, marked with a dashed oval, and the neutral loss C3H9N, 874 
indicated by a dashed arrow, occur in the spectra, and this fragmented metabolite could be annotated 875 
as an acylcarnitine. 876 
Figure 8: HCD type MS
2
 fragmentation spectra obtained at low (30NCE, A), middle (70NCE, B), 877 
and high (110NCE, C) energy for precursor mass 340.1755 m/z, with the proposed elemental formula 878 
of C17H25NO6. The key fragment C4H5O2, marked with a dashed oval, and the neutral loss C3H9N, 879 
indicated by a dashed arrow, occur in the spectra, and this fragmented metabolite could be annotated 880 
as an acylcarnitine. 881 
Figure 9: Scatterplot of the number of fragments counted between m/z 85 and the mass value of the 882 
precursor ion (i.e., fragmented annotated acylcarnitine) versus the theoretical mass value of the 883 
acylcarnitine in positive ionization mode. 884 
9. Supplementary Material 885 
Supplementary Table in Excel: Overview of acylcarnitines including spectral properties and Scifinder 886 
analysis. The rows represent the annotated acylcarnitine metabolites (including carnitine), and the 887 
rows (left to right) represent: the human urine extract number for which the scan number and 888 
retention time are noted in the Table (Urine file fragm); the scan number of the full scan in which the 889 
acylcarnitine is precursor ion (# MS1); the retention time in minutes (RT); the theoretical mass of the 890 
ionized acylcarnitine (m/z [M+H]
+
); the elemental formula of the ionized acylcarnitine (EF [M+H]
+
); 891 
the number of hits Scifinder returns on querying the (neutralized) elemental formula of the 892 
acylcarnitine (Hits Scifinder); the number of hits in Scifinder remainin after refining based on the 893 
(decharged) substructure of carnitine (Refine: Carnitine); the number of references to the most cited 894 
acylcarnitine returned by Scifinder (# refs Top hit); the number of fragments counted between m/z 85 895 
and the precursor ion (# fragm 85 – precurs); the number of oxygen atoms in the acylcarnitine minus 896 
the three carnitine oxygen atoms (# O atom minus 3); the carbon to hydrogen ratio (C:H), the 897 
presence (Y) or absence (N) of the annotated acylcarnitines in HMDB (Present in HMDB?); the 898 
annotation/identification of reported acylcarnitines, using the nomenclature of Zuniga and Li (Zuniga 899 
and Li, 2011) for acylcarnitines not present in databases (Annotation/Identification); the 900 
Metabolomics Standard Initiative Metabolite Identification level of the reported acylcarnitines (MSI 901 
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MI level); information on the metabolite annotation process (Spectra compared to / fragment 902 
analysis); and the SMILES string for level 2 or 1 identified structures (SMILES). 903 
All mzXML files of human urine extracts 1 – 7 that associated with this study are publicly available 904 
from the ‘AcylcarnitineManuscript’ folder of the ‘JVanDerHooft_Public’ repository at the 905 
MetabolomeExpress (Carroll et al., 2010)(Carroll et al., 2010) website (https://www.metabolome-906 
express.org). 907 
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